Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients

Qiao, Chun; Sun, Chao; Ouyang, Yong; Wang, Jujuan; Shen, Qian; Li, Jianyong; Zhang, Sujiang

doi:10.3324/haematol.2014.109199

Cited by 22 publications

(28 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, CALR mutations frequency in MPN patients in this study (27.37%) confirms previous findings in European patients (20-25%) [11,12,41]. These mutations were found in 74% [16] and 88% [11] of PMF WT JAK2 V617F patients, while in this study the reported frequency was 80%.…”

Section: Jak2supporting

confidence: 92%

“…These mutations were found in 74% [16] and 88% [11] of PMF WT JAK2 V617F patients, while in this study the reported frequency was 80%. Brazilian PMF patients showed higher frequencies of CALR mutations than Chinese [41,42] and Japanese [24] populations. Interestingly, CALR mutations frequencies in ET patients were similar to the reported in a Chinese study [42], but much lower than the frequencies reported by others [11,19,24,41].…”

Section: Jak2mentioning

confidence: 94%

“…Brazilian PMF patients showed higher frequencies of CALR mutations than Chinese [41,42] and Japanese [24] populations. Interestingly, CALR mutations frequencies in ET patients were similar to the reported in a Chinese study [42], but much lower than the frequencies reported by others [11,19,24,41]. It is noteworthy that the Brazilian population has a very diverse genetic background that is the result of more than five centuries of interethnic crossing of people from three continents: European, Amerindian and African [43][44][45][46].…”

Section: Jak2mentioning

confidence: 94%

See 2 more Smart Citations

CALR mutations screening in wild type JAK2V617F and MPLW515K/L Brazilian myeloproliferative neoplasm patients

Nunes

Lima

Chauffaille

et al. 2015

Blood Cells, Molecules, and Diseases

View full text Add to dashboard Cite

Section: Jak2supporting

confidence: 92%

Section: Jak2mentioning

confidence: 94%

Section: Jak2mentioning

confidence: 94%

See 1 more Smart Citation

CALR mutations screening in wild type JAK2V617F and MPLW515K/L Brazilian myeloproliferative neoplasm patients

Nunes

Lima

Chauffaille

et al. 2015

Blood Cells, Molecules, and Diseases

View full text Add to dashboard Cite

“…Four of the six eligible studies showed that CALR mutant-ET or PMF presented significantly higher OS rate than wtCALR ET or PMF as assessed through IPSET, IPSS, and DIPSS-plus (15,16,23,31). Our meta-analysis according to these six studies suggested significantly lower numbers in the high-risk groups (RR=0.53, 95% CI: 0.40-0.71).…”

Section: Risks For Patients With Calr Mutationmentioning

confidence: 83%

“…A total of 19 eligible studies were selected for the meta-analysis of the prevalence estimates (5, 6, 14-30) ( Table 1). Among these studies, four studies were selected for the meta-analysis of fibrotic transformation (15,19,31,32) (Table 2), five studies for the meta-analysis of leukemic transformation (15,16,29,31,33) (Table 3), and five studies for the meta-analysis of risks for patients with CALR mutation (15,16,18,23,31,33) (Table 4). The clinical features of the 21 studies published from 2013 to 2015 are summarized in Tables 1-4. A total of 3,141 patients with ET and 1,605 patients with PMF were enrolled to determine the prevalence estimates for patients with CALR mutation.…”

Section: Description Of the Studiesmentioning

confidence: 99%

Frequency of Calreticulin (CALR) Mutation and Its Clinical Prognostic Significance in Essential Thrombocythemia and Primary Myelofibrosis: A Meta-analysis

et al. 2016

View full text Add to dashboard Cite

Objective As the calreticulin (CALR) mutation frequency is significantly associated with essential thrombocythemia (ET) and primary myelofibrosis (PMF), this mutation may be an important biomarker in patients with ET and PMF. Methods We performed a literature search until April 2015 and obtained 21 relevant studies. The outcome was pooled as the effect size by using the Stata software program. Results The CALR mutation frequencies in patients with ET and PMF were 19% and 22%, respectively. The CALR mutation ratio in Asian patients with ET was 23% and higher than that in European-American patients (16%). Moreover, the mutation ratio in Asian patients with PMF was lower (21%) than that in European-American patients (23%). A slight trend toward fibrotic transformation was found in ET with CALR mutations, whereas leukemic transformation was not significant in patients with ET or PMF with CALR mutations. Conclusion CALR mutations significantly influence the incident of ET as demonstrated by the metaanalysis.

show abstract

Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis

Pei

Wang

et al. 2016

Ann Hematol

View full text Add to dashboard Cite

The understanding of genetic basis for Philadelphia-negative myeloproliferative neoplasm (MPN) has got much progress in recent years. But the effect of CALR vs. JAK2V617F mutations on the clinical progression and prognosis of primary fibrosis (PMF) remains relatively obscure. In this meta-analysis, we searched Pubmed, Embase, and Web of Science databases for observational studies published until February 2016. Researches that evaluated CALR vs. JAK2V617F mutations on PMF-relevant complications (splenomegaly, leukemic transformation, or thrombosis) and overall survival were selected. Pooled adjust odds ratio (OR), hazard risk (HR), and the corresponding 95 % confidence intervals (CI) were calculated for the CALR-mutant versus the JAK2-mutant categories. Twelve studies involving 435 CALR-mutated and 1116 JAK2V617F PMF patients were analyzed. CALR-mutated patients displayed a lower risk of splenomegaly (OR 0.47, 95 % CI 0.29-0.78) and thrombosis (OR 0.52, 95 % CI 0.29-0.92) but showed no significant difference in the risk of leukemic transformation (OR 0.90, 95 % CI 0.55-1.47) when compared with JAK2-mutated patients. CALR mutation favorably affected overall survival while JAK2 mutation led to poorer survival rate (HR 2.58, 95 % CI 2.08-3.20). This meta-analysis confirmed that a genetic classification of PMF by CALR and JAK2 mutations carried significant prognostic relevance.

show abstract

Clinical importance of different calreticulin gene mutation types in wild-type JAK2 essential thrombocythemia and myelofibrosis patients

Cited by 22 publications

References 13 publications

CALR mutations screening in wild type JAK2V617F and MPLW515K/L Brazilian myeloproliferative neoplasm patients

CALR mutations screening in wild type JAK2V617F and MPLW515K/L Brazilian myeloproliferative neoplasm patients

Frequency of Calreticulin (CALR) Mutation and Its Clinical Prognostic Significance in Essential Thrombocythemia and Primary Myelofibrosis: A Meta-analysis

Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis

Contact Info

Product

Resources

About